dc.contributor.author | Zinzani, PL | |
dc.contributor.author | Santoro, A | |
dc.contributor.author | Gritti, G | |
dc.contributor.author | Brice, P | |
dc.contributor.author | Barr, PM | |
dc.contributor.author | Kuruvilla, J | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Kline, J | |
dc.contributor.author | Johnson, NA | |
dc.contributor.author | Mehta-Shah, N | |
dc.contributor.author | Lisano, J | |
dc.contributor.author | Wen, R | |
dc.contributor.author | Akyol, A | |
dc.contributor.author | Moskowitz, AJ | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2023-09-18T15:15:36Z | |
dc.date.available | 2023-09-18T15:15:36Z | |
dc.date.issued | 2023-09-26 | |
dc.identifier | 496496 | |
dc.identifier.citation | Blood Advances, 2023, 7 (18), pp. 5272 - 5280 | en_US |
dc.identifier.issn | 2473-9529 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5965 | |
dc.identifier.eissn | 2473-9537 | |
dc.identifier.eissn | 2473-9537 | |
dc.identifier.doi | 10.1182/bloodadvances.2023010254 | |
dc.description.abstract | Patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL) have poor responses to salvage therapy. Nivolumab and brentuximab vedotin (BV) showed promising early efficacy in patients with R/R PMBL in the phase 1/2 open-label, multicenter CheckMate 436 study; we report safety and efficacy findings from the 3-year follow-up. Patients who were eligible were aged ≥15 years with R/R PMBL previously treated with either high-dose chemotherapy plus autologous hematopoietic cell transplantation (HCT) or ≥2 prior multiagent chemotherapies, and had Eastern Cooperative Oncology Group performance status scores of 0 to 1 and CD30 expression of ≥1%. Patients were treated with nivolumab 240 mg and BV 1.8 mg/kg once every 3 weeks until disease progression or unacceptable toxicity. Primary end point was objective response rate (ORR); secondary end points included complete response rate, duration of response, progression-free survival (PFS), and overall survival (OS). Safety was monitored throughout. At final database lock (30 March 2022), 29 patients had received nivolumab plus BV; median follow-up was 39.6 months. Investigator-assessed ORR was 73.3%; median time to response was 1.3 months (range, 1.1-4.8). Median PFS was 26.0 months; median OS was not reached. PFS and OS rates at 24 months were 55.5% (95% confidence interval [CI], 32.0-73.8) and 75.5% (95% CI, 55.4-87.5), respectively. The most frequently occurring grade 3/4 treatment-related adverse event was neutropenia. Consolidative HCT was received by 12 patients, with a 100-day complete response rate of 100.0%. This 3-year follow-up showed long-term efficacy for nivolumab plus BV in R/R PMBL, with no new safety signals. This trial was registered at www.clinicaltrials.gov as #NCT02581631. | |
dc.format | Print-Electronic | |
dc.format.extent | 5272 - 5280 | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | American Society of Hematology | en_US |
dc.relation.ispartof | Blood Advances | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.subject | Adult | |
dc.subject | Humans | |
dc.subject | Brentuximab Vedotin | |
dc.subject | Nivolumab | |
dc.subject | Follow-Up Studies | |
dc.subject | Hodgkin Disease | |
dc.subject | Neoplasm Recurrence, Local | |
dc.subject | Lymphoma, B-Cell | |
dc.title | Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-06-04 | |
dc.date.updated | 2023-09-18T15:14:49Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1182/bloodadvances.2023010254 | en_US |
rioxxterms.licenseref.startdate | 2023-09-26 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/37352266 | |
pubs.issue | 18 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.1182/bloodadvances.2023010254 | |
pubs.volume | 7 | |
icr.researchteam | Medicine (RMH) | en_US |
dc.contributor.icrauthor | Cunningham, David | |
icr.provenance | Deposited by Mr Arek Surman on 2023-09-18. Deposit type is initial. No. of files: 1. Files: blooda_adv-2023-010254-main.pdf | |